



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref.:ISLL: CH:2021

Date: 01st November, 2021

The President,
Listing Compliance Department
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUB: OUTCOME OF BOARD MEETING

Dear Sir,

Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") please note that the Board of Directors in their meeting held on today i.e. 01st November, 2021, have considered and approved the Standalone and Consolidated Un-audited Financial Results of Ind-Swift Laboratories Limited for the quarter and half year ended 30th September, 2021.

These Financial results are limited reviewed by the Statutory Auditors of the Company. The Limited Review Report as Submitted by the Statutory Auditors is also enclosed along with the Unaudited Financial Results.

The un-audited financial results of the Company will also be available on the website of the Company i.e. www.indswiftlabs.com.

The Board Meeting commenced at 3.00 P.M and concluded at 5.45 P.M.

You are requested to kindly take the same on record.

Thanking you,
For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
AVP-CORPORATE AFFAIRS &
COMPANY SECRETARY

Encl: As above

Avishkar Singhal & Associates

CHARTERED ACCOUNTANTS

LIMITED REVIEW

The Board of Directors
Ind-Swift Laboratories Ltd
SCO 850, NAC Manimajra
Chandigarh

We have reviewed the accompanying statement of unaudited standalone financial results of Ind-Swift Laboratories Ltd. for the Quarter ended 30.09.2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Avishkar Singhal & Associates
Chartered Accountants
FRN: 017362N

Place: Chandigarh
Date: 01.11.2021
UDIN: 21098689AAAHE5441


(CA Avishkar Singhal)
Partner
Mem. No. 098689

S.C.O. 2413-14, IIInd Floor, Sector – 22 C, Chandigarh-160022

Phone: 0172-5088885, E-mail: avishkarsmail@gmail.com

Mobile: 98146-02890, 98880-04461, 98146-12817



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH, SEPT 2021						
CIN L24232CH1995PLC015553						
	Rs. In Lacs					
	STANDALONE					
Particulars	Quarter Ended 30.09.2021	Quarter Ended 30.06.2021	Quarter Ended 30.09.2020	Half Year Ended 30.09.21	Half Year Ended 30.09.20	Year Ended 31.03.2021
	Audited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
Income from Operations:						
Revenue from operations	22992.45	24264.99	22119.91	47197.44	42505.36	85657.84
Other Income	714.63	594.96	579.40	1309.59	1172.21	2312.78
Total Revenue	23707.08	24799.95	22699.30	48507.03	43677.58	87970.62
EXPENSES:						
a. Cost of Materials Consumed	11856.61	12034.96	12545.28	23951.56	20585.01	42747.15
b. Purchase of stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
c. (Increase) /decrease in FG, WIP & stock in trade	(1572.00)	(215.74)	(2408.85)	(1787.73)	141.55	(247.65)
d. Employee benefit	2910.49	2828.06	2914.51	5738.55	5102.18	10416.71
e. Finance Costs	2419.19	2412.14	2495.57	4831.34	4999.82	10021.57
f. Depreciation	1387.37	1405.68	1984.54	2793.05	3953.05	8729.17
g. Other expenditure	4320.10	4391.91	4245.88	8712.01	7556.75	14691.93
TOTAL EXPENSES	21321.78	22917.00	21776.92	44238.78	42338.33	86358.91
Profit(loss) before exceptional items and Tax	2385.31	1882.94	922.38	4268.25	1339.25	1611.72
Exceptional items (Income) /loss	0.00	0.00	0.00	0.00	0.00	0.00
Profit(loss) before Tax (After exceptional items)	2385.31	1882.94	922.38	4268.25	1339.25	1611.72
Tax Expenses :-						
Current Tax	0.00	0.00	0.00	0.00	0.00	69.28
Mat Credit Entitlement	0.00	0.00	0.00	0.00	0.00	(69.28)
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	1103.94
Deferred Tax	0.00	0.00	0.00	0.00	0.00	947.60
Income Tax Adjustment of Previous Years	0.00	7.77	0.00	7.77	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	2385.31	1875.17	922.38	4260.48	1339.25	(439.83)
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the period after tax & Exceptional items	2385.31	1875.17	922.38	4260.48	1339.25	(439.83)
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) Items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	0.00	151.90
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	0.00	0.00	0.00	151.90
Total Comprehensive Income for the Period	2385.31	1875.17	922.38	4260.48	1339.25	(591.73)
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						36813.40
EPS (of Rs. 10/- each) (Net annualised)						
Basic	4.04	3.17	1.56	7.21	2.27	(0.74)
Diluted	4.04	3.17	1.56	7.21	2.27	(0.74)

For Ind-Swift Laboratories Limited

N.R. Munjal

N.R. Munjal

Chairman and Managing Director

Place: Chandigarh

Date: 01.11.2021



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED		
Standalone Statement of Assets & Liabilities :		
	UnAudited	Audited
	30-Sep-21	Rs. In Lakhe 31-Mar-21
ASSETS		
Non-current assets :		
Property, Plant and Equipment	71,140.87	73,468.04
Right of Use - Land	188.52	189.68
Capital work-in progress	1,527.10	1,070.21
Investment property	1,462.68	1,476.87
Other Intangible assets	53.02	106.05
Intangible assets under development	862.06	814.08
Financial Assets		
a) Investments		
- In subsidiaries and associates	4,964.44	4,964.44
- In Others	568.80	568.80
b) Other Non-current Financial Assets	279.62	244.19
Deferred tax assets (net)	5,884.26	5,884.26
Other non-current assets	6,344.22	6,352.82
TOTAL NON- CURRENT ASSETS	93,375.59	95,139.43
Current Assets		
inventories	37,679.98	35,441.15
Financial Assets		
(a) Trade receivables	42,456.44	40,014.65
(b) Cash and cash equivalents	1,196.66	995.24
(c) Other current financial Assets	4,031.46	5,414.29
Other current assets	4,099.29	4,485.55
Assets held-for-sale	200.95	229.59
Total Current Assets	89,664.77	86,580.47
Grand total	183,040.36	181,719.89
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	5,980.58	5,980.58
(b) Other Equity	62,149.00	57,888.52
Total Equity	68,129.58	63,869.10
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	86,756.50	87,541.03
(b) Lease liabilities	48.06	48.21
Provisions	1,680.36	1,572.66
Other Non current Liabilities	16.14	17.41
Total Non-Current Liabilities	88,501.06	89,179.30
Current liabilities		
Financial Liabilities		
(a) Borrowings	9,576.35	12,055.81
(b) Lease liabilities	2.72	2.72
(c) Trade payables	11,906.40	12,395.55
(d) Other Financial Liabilities	676.45	830.22
(e) Current Provisions	69.28	69.28
Other current liabilities	4,178.53	3,317.90
Total Current Liabilities	26,409.73	28,671.49
Grand Total	183,040.36	181,719.89



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED		
STANDALONE CASH FLOW STATEMENT FOR YEAR ENDED 30.09.2021		
	Year ended 30.09.2021	Year ended 31.03.2021
	Rs in Lacs	
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Extra-Ordinary Items	4,268.25	1,611.71
ADJUSTMENTS FOR:		
i) Depreciation	2,793.05	8,729.17
ii) Exchange (profit)/loss	(9.23)	182.62
iii) Interest on Term loans, NCDS & FD	4,471.41	9,076.70
iv) Interest received	-	(51.28)
v) Loss/(Profit) on sale of fixed assets	10.55	-
vi) Income tax adj of previous years	(7.77)	-
vii) Amortisation of Subsidy	(2.53)	(2.53)
viii) Provision for Interest on CC	-	-
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	11,523.73	19,546.39
ADJUSTMENTS FOR:		
i) Trade & Other Receivables	(2,429.80)	(1,799.45)
ii) Inventories	(2,238.83)	(1,159.32)
iii) Other assets	1,588.48	(2,983.16)
iv) Current Liabilities	477.67	85.14
v) Working Capital Borrowing	(1,057.06)	(186.43)
vi) Income taxes (Including Advance Tax/TDS)	-	-
Net Cash flow from operating Activities	7,864.20	13,503.17
B. CASH FLOW FROM INVESTING ACTIVITIES		
i) Purchase of fixed Assets Tangible	(936.31)	(391.04)
ii) Purchase of fixed Assets Intangible	(47.98)	(48.62)
iii) Sale of fixed assets	-	-
iv) (Purchase)/ Sale of Investments	-	(628.78)
v) Interest Received	-	51.28
Net Cash from investing activities	(984.29)	(1,017.16)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Term Loans to Banks & Financial Institutions & FD	(1,922.88)	(3,985.29)
ii) Interest paid on Term Loans & FD	(4,755.62)	(8,389.40)
iii) Proceeds from Term Loans From Banks & Financial Institutions	-	-
Net Cash flow from Financing Activities	(6,678.49)	(12,374.69)
Net increase in Cash or Cash Equivalents	201.41	111.32
Opening Cash & Cash Equivalents	995.24	883.93
Closing Cash & Cash Equivalents	1,196.66	995.24
Add; unrealised Gain/(loss) in FCTR	-	-
Closing Cash & Cash Equivalents after FCTR	1,196.66	995.24

Avishkar Singhal & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to date Financial Results of the company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The Board of Directors
Ind-Swift Laboratories Ltd
SCO 850, NAC Manimajra
Chandigarh

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Ind -Swift Laboratories Ltd. ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit before tax for the quarter ended 30.09.2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matter, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

S.C.O. 2413-14, IIInd Floor, Sector – 22 C, Chandigarh-160022

Phone: 0172-5088885, E-mail: avishkarsmail@gmail.com

Mobile: 98146-02890, 98880-04461, 98146-12817

4) The Statement includes the results of:

Particulars	Name
Subsidiary Company	Ind Swift Laboratories Inc. USA Ind-Swift Middle East FZE (UAE) Meteoric Life Science Pte Ltd., Singapore Halcyon Life Sciences Pvt Ltd Fortune (India) Constructions Ltd

- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of five subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/financial information/financial results reflect total revenue of Rs 5.72 Crores, total net profit before tax of Rs 1.25 crores and total comprehensive income of Rs 0.62 Crores, for the quarter ended 30.09.2021 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/financial information/financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For Avishkar Singhal & Associates

Chartered Accountants

FRN: 017362N



(CA Avishkar Singhal)

Partner

Mem. No. 098689

Place: Chandigarh

Date: 01.11.2021

UDIN: 21098689AAAAHF2106



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH, SEPT 2021						
CIN L24232CH1995PLC015553						
	Rs. In Lacs					
	CONSOLIDATED					
Particulars	Quarter Ended 30.09.2021	Quarter Ended 30.06.2021	Quarter Ended 30.09.2020	Half Year Ended 30.09.21	Half Year Ended 30.09.20	Year Ended 31.03.2021
Audited	UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
Income from Operations:						
Revenue from operations	23564.35	24980.20	22827.04	48544.55	43853.94	89134.45
Other Income	714.63	595.02	536.18	1309.65	1129.00	2269.74
Total Revenue	24278.98	25575.22	23363.23	49854.20	44982.94	91404.19
EXPENSES:						
a. Cost of Materials Consumed	12054.55	12675.03	13000.21	24729.57	21494.87	45091.49
b. Purchase of stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
c. (Increase) / decrease in FG, WIP & stock in trade	(1572.00)	(215.74)	(2408.85)	(1787.73)	141.55	(247.65)
d. Employee Benefit	7983.12	2887.35	2970.68	5870.47	5217.20	16655.68
e. Finance Costs	2419.20	2412.14	2495.57	4831.34	4999.82	10021.59
f. Depreciation	1390.83	1405.68	1984.54	2796.51	3953.05	8729.17
g. Other expenditure	4493.07	4509.02	4328.88	9002.09	7727.04	15052.60
TOTAL EXPENSES	21768.77	23673.48	22371.03	45442.25	43533.53	89603.34
Profit(loss) before exceptional items and Tax	2510.21	1901.75	992.20	4411.96	1449.42	1800.85
Exceptional Items (Income) / loss	0.00	0.00	0.00	0.00	0.00	0.00
Profit(loss) before Tax (After exceptional items)	2510.21	1901.75	992.20	4411.96	1449.42	1800.85
Tax Expenses :-						
Current Tax	63.15	13.57	0.00	76.72	0.00	133.31
Mat Credit Entitlement	0.00	0.00	0.00	0.00	0.00	(53.28)
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	1103.94
Deferred Tax	0.00	0.00	0.00	0.00	0.00	947.60
Income Tax Adjustment of Previous Years	0.00	7.77	0.00	7.77	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	2447.05	1880.41	992.20	4327.47	1449.42	(314.72)
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the period after tax & Exceptional items)	2447.05	1880.41	992.20	4327.47	1449.42	(314.72)
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	0.00	151.90
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	0.00	0.00	0.00	151.90
Total Comprehensive Income for the Period	2447.05	1880.41	992.20	4327.47	1449.42	(466.61)
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						33294.91
EPS (of Rs. 10/- each) (Not annualised)						
Basic	4.14	3.18	1.68	7.32	2.45	(0.53)
Diluted	4.14	3.18	1.58	7.32	2.45	(0.53)

Place: Chandigarh
 Date: 01.11.2021

For Ind-Swift Laboratories Limited

 N.R. Munjal
 Chairman and Managing Director

Works : Barwala Road, Vill. Bhagwanpur, Near Dera Bassi, Distt. Mohali (Punjab)
 Tel. : ++ 91-1762-281072, Telefax : ++91-1762-281073



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED		
Consolidated Statement of Assets & Liabilities		
	UnAudited	Audited
ASSETS		Rs. In Lakhs
Non-current assets :	30-Sep-21	31-Mar-21
Property, Plant and Equipment	71,218.01	73,548.64
Right of Use - Land	188.52	189.68
Capital work-in progress	1,527.10	1,070.21
Investment property	1,462.68	1,476.87
Other Intangible assets	74.15	127.17
Intangible assets under development	862.06	814.08
Financial Assets		
a) Investments		
- In subsidiaries and associates		
- In Others	3,498.83	3,552.84
b) Other Non-current Financial Assets	286.62	611.43
Deferred tax assets (net)	6,035.87	6,035.87
Other non-current assets	-	-
TOTAL NON- CURRENT ASSETS	85,253.84	87,426.79
Current Assets		
Inventories		
Financial Assets	39,699.98	37,566.66
(a) Trade receivables		
(b) Cash and cash equivalents	44,540.32	43,238.79
(c) Other current financial Assets	1,731.71	1,160.06
Other current assets	4,031.46	5,414.29
Assets held-for-sale	6,770.74	6,808.69
Total Current Assets	200.95	229.59
Grand total	97,075.16	94,418.08
	182,328.99	181,844.98
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	5,980.58	5,980.58
(b) Other Equity	58,706.36	54,370.03
Equity attributable to equity holders of the Company	64,686.94	60,350.61
(c) Minority interest	(17.47)	(8.97)
Total Equity	64,669.47	60,341.64
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	87,628.12	88,412.65
(b) Lease liabilities	48.06	48.21
Provisions	1,680.36	1,572.66
Other Non current Liabilities	16.14	17.41
Total Non-Current Liabilities	89,372.68	90,050.93
Current liabilities		
Financial Liabilities		
(a) Borrowings	9,594.72	12,071.81
(b) Lease liabilities	2.72	2.72
(c) Trade payables	12,229.22	13,882.08
(d) Other Financial Liabilities	676.45	830.22
(e) Other current liabilities	4,921.40	3,820.37
(f) Provision	95.71	98.01
Foreign Currency Translation	766.61	747.09
Total Current Liabilities	28,286.84	31,452.31
Grand Total	182,328.99	181,844.88





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED		Rs in Lacs
CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2021		
	Year ended 30.09.2021	Year ended 31.03.2020
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Extra-Ordinary Items	4411.96	(1,977.12)
ADJUSTMENTS FOR:		
i) Depreciation	2,796.51	9,005.93
ii) Exchange (profit)/loss	(9.23)	(575.44)
iii) Interest on Term loans, NCDS, OCDs & FD	4,471.41	9,247.34
iv) Interest received	-	(58.73)
v) Loss/(Profit) on sale of fixed assets	-	(6.50)
vi) Income tax adj of previous years	-	(40.49)
vii) Amortisation of Subsidy	(2.53)	(2.53)
viii) Provision for Interest on CC	-	32.58
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	11,668.12	15,625.04
ADJUSTMENTS FOR:		
i) Trade & Other Receivables	(1,389.53)	(3,839.52)
ii) Inventories	(2133.31)	(2,620.88)
iii) Other assets	1535.91	1,920.89
iv) Current Liabilities	(446.90)	1,635.16
v) Working Capital Borrowing	(1057.06)	(196.90)
vi) Income taxes (Including Advance Tax/TDS)	76.72	-
	(3414.16)	(3101.24)
Net Cash flow from operating Activities	8253.96	12523.80
B. CASH FLOW FROM INVESTING ACTIVITIES		
i) Purchase of fixed Assets Tangible	(936.31)	(1,074.31)
ii) Purchase of fixed Assets Intangible	(47.98)	(42.25)
iii) Sale of fixed assets	0.00	37.10
iv) (Purchase)/ Sale of Investments	0.00	110.89
v) Interest Received	0.00	58.73
Net Cash from investing activities	(984.29)	(909.85)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Term Loans to Banks & Financial Institutions & FD	(1922.88)	(6,574.22)
ii) Interest paid on Term Loans & FD	(4755.62)	(6,751.67)
iii) Proceeds from Term Loans From Banks & Financial Institutions	0.00	-
Net Cash flow from Financing Activities	(6,678.49)	(13,325.90)
Net increase in Cash or Cash Equivalents	591.17	(1,711.95)
Opening Cash & Cash Equivalents	1160.06	2,996.80
Closing Cash & Cash Equivalents	1731.71	1,058.23
Add; unrealised Gain/(loss) in FCTR	19.52	226.62
Closing Cash & Cash Equivalents after FCTR	1,751.23	1,284.85





Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Notes: -

1. During this quarter Ended September 2021 company has earned Standalone EBITDA of Rs. 6115.91 lakhs against EBITDA of Rs. 5332.85 lakhs for quarter ended September, 2020 and Standalone Net profit for the current quarter is Rs 2385.31 lakhs as compared to Net profit of Rs. 922.38 Lakhs for corresponding quarter of previous year.
2. The un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2021 in respect of Ind-Swift Laboratories Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 01, 2021. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
3. The above is an extract of the detailed format of the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2021 filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the full format of the standalone and consolidated Financial Results for the quarter and half year ended September 30, 2021 are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.indswiftlabs.com.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. The consolidated financial results include the financial results of the parent company Ind- Swift Laboratories Limited and the financial results of the following subsidiaries:
 - a) Ind-Swift Laboratories Inc., USA
 - b) Meteoric Life Sciences Pte. Ltd., Singapore
 - c) Ind-Swift Middle East FZ-LLC, UAE
 - d) Fortune (India) Constructions Ltd
 - e) Halcyon Life Sciences Pvt Ltd

Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.

6. No adjustment has been made in respect of Deferred Taxes & current Tax as per Ind-AS 12, as the same would be provided at year end.

Handwritten signature/initials





Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



7. In March 2020, the World Health Organization declared COVID-19 to be a pandemic. The Group has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Group has considered internal and external information while finalizing various estimates in relation to its financial statement captions upto the date of approval of the financial statements by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Group will continue to closely monitor any material changes to future economic conditions.
8. Company has not classified any amount in Exceptional Items during the quarter ended September 30, 2021.
9. Additional disclosures as per regulation 52(4) and other regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 are as follows:

A. Credit Rating and change in credit rating (if any)	The Non Convertible Debentures issued by the company are rated B Stable by Care Rating.
B. Assets cover available, in case of NCD	1.94 times of total liability of outstanding NCDs as on 30 th September, 2021. The nature of security is first pari passu charge over the entire fixed assets (both present and future).
C. Previous due date for payment of interest/repayment of principal of non convertible debt securities and same has been paid or not	Previous due date for payment of interest was 31 st October, 2021 and the same has been paid within the due date. Principal payment is yet to be started.
D. Next due date for payment of interest /principal of non convertible debt securities payable and optionally convertible debentures and redemption	The interest on NCD/OCD is due on 30 th November, 2021. Principal payment of debt securities is yet to be started.
E. Debt-Equity Ratio	2.02
F. Debt Service Coverage Ratio	1.83
G. Interest Service Coverage Ratio	2.53
H. Debenture Redemption Reserve (DRR) :	Not Required. Ministry of Corporate Affairs vide its notification dated 16 th August, 2019, had exempted listed companies to maintain DRR.
I. Net Worth (Rs. In lacs) :	47,768.86
J. Paid up Capital (Rs. In lacs) :	5908.69
k. Net Profit after Tax for quarter ended Sept21 (Rs. In lacs)	2385.31
L. Earnings Per Share for quarter ended Sept21	4.04



Ind-Swift LABORATORIES LIMITED


(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



10. The previous period figures have been re-grouped and re-arranged wherever necessary.
11. The Company is exclusively in the Pharmaceutical Business segment.

Place : Chandigarh
Date: 01.11.2021

For IND-SWIFT LABORATORIES LTD

N.R. Munjal
Chairman and Managing Director